• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不仅仅是味觉问题:解决化疗引起的味觉障碍存在多维度差距。

More than a taste ıssue: multidimensional gaps in addressing chemotherapy-ınduced dysgeusia.

作者信息

Uyar Galip Can

机构信息

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.

出版信息

Support Care Cancer. 2025 Jun 13;33(7):572. doi: 10.1007/s00520-025-09628-x.

DOI:10.1007/s00520-025-09628-x
PMID:40506604
Abstract

Chemotherapy-induced taste alterations are a prevalent but frequently under-recognized complication with significant nutritional and psychosocial consequences. In this letter, we offer a critical appraisal of the recent study by Köksal et al., highlighting key gaps that limit its translational applicability. We emphasize the importance of accounting for comorbid conditions, psychosocial impacts, and treatment-specific factors-such as variability among chemotherapeutic agents and adjunct medications. Additionally, we advocate for a multidisciplinary approach to better address dysgeusia in clinical oncology. Our commentary aims to broaden the clinical perspective on dysgeusia and support more comprehensive supportive care strategies.

摘要

化疗引起的味觉改变是一种普遍存在但常未被充分认识的并发症,会产生重大的营养和心理社会后果。在这封信中,我们对Köksal等人最近的研究进行了批判性评估,突出了限制其转化应用的关键差距。我们强调考虑合并症、心理社会影响以及特定治疗因素(如化疗药物和辅助药物之间的差异)的重要性。此外,我们主张采用多学科方法,以更好地解决临床肿瘤学中的味觉障碍问题。我们的评论旨在拓宽对味觉障碍的临床视野,并支持更全面的支持性护理策略。

相似文献

1
More than a taste ıssue: multidimensional gaps in addressing chemotherapy-ınduced dysgeusia.不仅仅是味觉问题:解决化疗引起的味觉障碍存在多维度差距。
Support Care Cancer. 2025 Jun 13;33(7):572. doi: 10.1007/s00520-025-09628-x.
2
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织(EORTC)癌症贫血患者促红细胞生成蛋白使用指南:2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.成人止吐药预防中度或高度致吐性化疗引起的恶心和呕吐:网状荟萃分析。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.
6
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.大麻素用于接受化疗的成年癌症患者的恶心和呕吐治疗。
Cochrane Database Syst Rev. 2015 Nov 12;2015(11):CD009464. doi: 10.1002/14651858.CD009464.pub2.
7
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
8
Influence of salivary tumor necrosis factor alpha (TNF-α) concentration in patients with dysgeusia induced by antineoplastic chemotherapy: A case-control study.抗肿瘤化疗所致味觉障碍患者唾液肿瘤坏死因子α(TNF-α)浓度的影响:一项病例对照研究。
Arch Oral Biol. 2025 Sep;177:106318. doi: 10.1016/j.archoralbio.2025.106318. Epub 2025 Jun 4.
9
Systemic Inflammatory Response Syndrome全身炎症反应综合征
10
Pharmacotherapy for anxiety and comorbid alcohol use disorders.焦虑症合并酒精使用障碍的药物治疗
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2.

本文引用的文献

1
The effect of taste alteration on malnutrition and quality of life in patients undergoing chemotherapy.味觉改变对化疗患者营养不良及生活质量的影响。
Support Care Cancer. 2025 Apr 10;33(5):369. doi: 10.1007/s00520-025-09431-8.
2
Evaluation of the effects of thyroid functions on frailty in geriatric patients using the Edmonton, SOF and FRAIL Scales.使用埃德蒙顿量表、SOF量表和衰弱量表评估甲状腺功能对老年患者衰弱的影响。
BMC Geriatr. 2024 Dec 31;24(1):1051. doi: 10.1186/s12877-024-05643-5.
3
Taste-taste associations in chemotherapy-induced subjective taste alterations: findings from a questionnaire survey in an outpatient clinic.
化疗引起的主观味觉改变的味觉关联:门诊问卷调查的结果。
Support Care Cancer. 2023 Sep 2;31(9):552. doi: 10.1007/s00520-023-08013-w.
4
Characteristics of taste alterations in people receiving taxane-based chemotherapy and their association with appetite, weight, and quality of life.接受基于紫杉烷类化疗的患者味觉改变的特征及其与食欲、体重和生活质量的关系。
Support Care Cancer. 2021 Sep;29(9):5103-5114. doi: 10.1007/s00520-021-06066-3. Epub 2021 Feb 18.
5
ESPEN guidelines on nutrition in cancer patients.ESPEN 肿瘤患者营养指南。
Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6.
6
Value: Changes in the Detection and Recognition Thresholds of Three Basic Tastes in Lung Cancer Patients Receiving Cisplatin and Paclitaxel and Its Association with Nutritional and Quality of Life Parameters.价值:接受顺铂和紫杉醇治疗的肺癌患者三种基本味觉的检测和识别阈值变化及其与营养和生活质量参数的关联
Nutr Cancer. 2016;68(2):241-9. doi: 10.1080/01635581.2016.1144075. Epub 2016 Mar 4.
7
Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: prevalence, course of severity, and quality of life correlates.接受化疗的乳腺癌和妇科癌症患者的味觉改变:患病率、严重程度的变化过程以及与生活质量的相关性。
Acta Oncol. 2012 Apr;51(4):490-6. doi: 10.3109/0284186X.2011.633554. Epub 2011 Nov 30.
8
Taste alterations in cancer patients receiving chemotherapy: a neglected side effect?癌症患者化疗后味觉改变:被忽视的副作用?
Oncologist. 2010;15(8):913-20. doi: 10.1634/theoncologist.2009-0333. Epub 2010 Jul 28.
9
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres.法国综合癌症中心营养不良的流行情况、风险因素和临床意义。
Br J Cancer. 2010 Mar 16;102(6):966-71. doi: 10.1038/sj.bjc.6605578. Epub 2010 Feb 16.
10
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.用于在ICD-9-CM和ICD-10管理数据中定义合并症的编码算法。
Med Care. 2005 Nov;43(11):1130-9. doi: 10.1097/01.mlr.0000182534.19832.83.